MannKind's Afrezza Approved for Pediatric Use, Final Postmarketing Requirement Met
Summary
The FDA has approved MannKind's Afrezza for pediatric use in children aged 6 and older with Type 1 and Type 2 diabetes. This significant regulatory win also fulfills the final postmarketing requirement from Afrezza's original 2014 approval. This expands Afrezza's addressable market to over 350,000 children and adolescents. More importantly, the closure of the final postmarketing requirement removes a substantial regulatory and financial burden, significantly de-risking the drug's long-term outlook and opening new revenue potential.
At the time of this announcement, MNKD was trading at $3.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.23 to $6.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.